A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair - PubMed (original) (raw)

Review

. 2008 Aug 1;26(22):3785-90.

doi: 10.1200/JCO.2008.16.0812. Epub 2008 Jun 30.

Affiliations

• PMID: 18591545
• DOI: 10.1200/JCO.2008.16.0812

Review

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

Alan Ashworth. J Clin Oncol. 2008.

Abstract

Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic instability. This can foster tumorigenesis but also provides a weakness in the tumor that can be exploited therapeutically. Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCA2, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase. This provides the basis for a novel synthetic lethal approach to cancer therapy.

PubMed Disclaimer

Similar articles

• Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
  Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Dedes KJ, et al. Cell Cycle. 2011 Apr 15;10(8):1192-9. doi: 10.4161/cc.10.8.15273. Epub 2011 Apr 15. Cell Cycle. 2011. PMID: 21487248 Free PMC article.
• [Cancer therapy by PARP inhibitors].
  Seimiya H. Seimiya H. Nihon Rinsho. 2015 Aug;73(8):1330-5. Nihon Rinsho. 2015. PMID: 26281686 Review. Japanese.
• [PARP inhibitors--theoretical basis and clinical application].
  Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P. Dębska S, et al. Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. doi: 10.5604/17322693.999033. Postepy Hig Med Dosw (Online). 2012. PMID: 22706117 Review. Polish.
• Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
  Chalmers AJ, Lakshman M, Chan N, Bristow RG. Chalmers AJ, et al. Semin Radiat Oncol. 2010 Oct;20(4):274-81. doi: 10.1016/j.semradonc.2010.06.001. Semin Radiat Oncol. 2010. PMID: 20832020 Review.
• Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
  Kyle S, Thomas HD, Mitchell J, Curtin NJ. Kyle S, et al. Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297. Br J Radiol. 2008. PMID: 18820000

Cited by

• Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
  Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. Bundred N, et al. Invest New Drugs. 2013 Aug;31(4):949-58. doi: 10.1007/s10637-012-9922-7. Epub 2013 Jan 13. Invest New Drugs. 2013. PMID: 23315029 Clinical Trial.
• PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.
  Brunner A, Suryo Rahmanto A, Johansson H, Franco M, Viiliäinen J, Gazi M, Frings O, Fredlund E, Spruck C, Lehtiö J, Rantala JK, Larsson LG, Sangfelt O. Brunner A, et al. Elife. 2020 Jul 6;9:e57894. doi: 10.7554/eLife.57894. Elife. 2020. PMID: 32628111 Free PMC article.
• A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein.
  Bhat DS, Spies MA, Spies M. Bhat DS, et al. DNA Repair (Amst). 2022 Dec;120:103421. doi: 10.1016/j.dnarep.2022.103421. Epub 2022 Oct 27. DNA Repair (Amst). 2022. PMID: 36327799 Free PMC article. Review.
• Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.
  Murata S, Zhang C, Finch N, Zhang K, Campo L, Breuer EK. Murata S, et al. Biomed Res Int. 2016;2016:2346585. doi: 10.1155/2016/2346585. Epub 2016 Aug 24. Biomed Res Int. 2016. PMID: 27642590 Free PMC article. Review.
• Resistance to PARP-Inhibitors in Cancer Therapy.
  Montoni A, Robu M, Pouliot E, Shah GM. Montoni A, et al. Front Pharmacol. 2013 Feb 27;4:18. doi: 10.3389/fphar.2013.00018. eCollection 2013. Front Pharmacol. 2013. PMID: 23450678 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal